Caption Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Caption Management’s Portfolio CERE Stock Details CERE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-260,000	Closed	-$10.6M	–	1668
2024 Q2	$10.6M	Buy	+260,000	New	+$10.8M	0.16%	133
2024 Q1	–	Sell	-112,500	Closed	-$4.77M	–	1761
2023 Q4	$4.77M	Buy	+112,500	New	+$3.23M	0.06%	351
2023 Q3	–	Sell	-30,000	Closed	-$954K	–	1622
2023 Q2	$954K	Buy	+30,000	New	+$921K	0.02%	672
2022 Q3	–	Sell	-32,400	Closed	-$857K	–	1930
2022 Q2	$857K	Buy	+32,400	New	+$920K	0.01%	933

Other funds holding CERE

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

BTI

Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Caption Management's CERE Position: Q3 2022 in Review

Caption Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 36,400 shares — an estimated $962K sold.

Caption Management first reported a position in CERE in Q2 2022 and held it in 1 quarter. The position peaked at $962K in Q2 2022. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

Caption Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Caption Management sold 36,400 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $962K.
Caption Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
Caption Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $962K in Q2 2022.
114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on Caption Management's 13F filing for Q3 2022, filed 14 Nov 2022.